Core Insights - Journey Medical Corp (NASDAQ: DERM) is recognized as one of the best-performing micro-cap stocks in 2025, with a Buy rating reaffirmed by Lake Street analyst Thomas Flaten and a price target of $13 [1]. Group 1: Clinical Trial Results - Journey Medical published positive results from a Phase 1 clinical trial for Emrosi, an FDA-approved oral medication for skin conditions, in the Journal of Drugs in Dermatology [2]. - The trial met all three primary endpoints: no significant microbiome changes in skin, no notable antibiotic resistance to minocycline, and no major rise in opportunistic organisms compared to placebo [3]. - Emrosi is well tolerated with no significant safety concerns, supporting its low-dose profile to minimize disruption to normal body flora for safe, extended use in rosacea patients [3]. Group 2: Product Development and Approval - Emrosi received FDA approval in November 2024, making it the only oral therapy approved for treating both inflammatory lesions and redness in rosacea, supported by two Phase 3 clinical trials conducted in the US and Germany [5]. - Journey Medical Corp focuses on developing and marketing prescription dermatology products, with a portfolio that includes treatments for acne, rosacea, actinic keratosis, and fungal infections [6]. Group 3: Leadership Insights - Claude Maraoui, co-founder, president, and CEO of Journey Medical, emphasized that the publication reinforces Emrosi's differentiated benefits as a low-dose option that avoids significant microbial disruption or resistance, based on consistent data across trials [4].

Core Insights - The article discusses the strong performance of micro-cap stocks in 2025, highlighting that they experienced significant growth during a year characterized by an "everything rally" across various asset classes [2][3]. Market Performance - The Dow Jones US Micro-Cap Total Stock Market Index gained 12.59% in 2025, while the S&P 500 achieved nearly 17% [2]. - The Russell Micro-Cap Index saw a remarkable recovery, returning 17.03% in Q3 2025 after a 14.39% decline in Q1 [3]. Investment Outlook - Analysts believe that smaller companies are set for meaningful rebounds in 2026, driven by improved macroeconomic conditions and a shift away from speculative stocks [4]. - Factors contributing to this positive outlook include moderated inflation, easing conflicts, stabilized energy prices, and anticipated interest rate cuts by central banks [4]. Methodology for Stock Selection - Micro-cap stocks were defined as companies with market capitalizations between $50 million and $300 million, focusing on those with the strongest year-to-date performance in 2025 [7]. - Hedge fund sentiment was also considered based on Q3 2025 13F filing data [8]. Notable Micro-Cap Stocks - **Duos Technologies Group Inc (NASDAQ:DUOT)**: Market capitalization of $205.17 million with a YTD performance of 49.20%. The company received a price target increase from $11.50 to $14.00 due to a major contract and its leadership in train check services [9][10]. - **Journey Medical Corp (NASDAQ:DERM)**: Market capitalization of $150.49 million with a YTD performance of 80.99%. The company reaffirmed a Buy rating with a $13 price target following positive results from a Phase 1 clinical trial for its FDA-approved medication Emrosi [13][15].

As filed with the Securities and Exchange Commission on December 15, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FORTRESS BIOTECH, INC. (Exact name of registrant as specified in its charter) Delaware 20-5157386 (State or other jurisdiction of incorporation or organization) 1111 Kane Concourse, Suite 301 Bay Harbor Islands, FL 33154 (Address, including zip code, and telephone number, includ ...

Fund Performance - The Summers Value Fund LP achieved a net return of 20.4% in Q3 2025, outperforming the Russell 2000 Index ETF (12.4%) and the Russell 2000 Value Index ETF (12.5%) [2] - Year-to-date, the Fund is up 4.9%, lagging behind the IWM (10.3%) and IWN (8.9%) [2] - Since inception, the Fund has delivered a 12.2% annualized net return compared to 6.8% for IWM and 6.1% for IWN [2][3] Healthcare Sector Overview - The healthcare sector has faced challenges leading to underperformance against broader indexes, influenced by regulatory uncertainty from new FDA leadership and budget pressures at federal agencies [4] - Investors withdrew approximately $13 billion from healthcare funds in 2025, indicating a record annual outflow, while large-cap stocks saw $224 billion in inflows [5] - Despite negative sentiment, the healthcare sector is viewed as defensive and growing, with potential for disciplined investors to find opportunities [5][6] Investment Opportunities - The Fund has increased exposure to biopharma stocks, anticipating outperformance due to an innovation cycle and potential acquisitions by large-cap companies [6] - Notable contributors to the Fund's performance in Q3 included Zimvie (124% acquisition premium), Liquidia (strong sales of Yutrepia), and Consensus Cloud Solutions (return to positive revenue growth) [7] - The Fund initiated a position in uniQure following promising Phase 3 results for its gene therapy drug, which showed a 75% reduction in disease progression [9] Position Updates - Journey Medical, with a market cap of $175 million, launched Emrosi for rosacea treatment, with annualized sales approaching $30 million and potential peak sales exceeding $100 million [12] - Ligand Pharmaceuticals, valued at $3.7 billion, operates as a royalty aggregator and is expected to see strong performance from its drugs Ohtuvaryre and Filspari, with blockbuster potential [13][14] - The Fund's top five holdings include Electromed, Consensus Cloud Solutions, Liquidia, Spok Holdings, and Ligand Pharmaceuticals, with a significant allocation to pharmaceutical and biotechnology stocks [10]

Group 1: Fund Performance - Summers Value Fund LP achieved a net return of 20.4% in Q3 2025, outperforming the Russell 2000 Index ETF and the Russell 2000 Value Index ETF, which returned 12.4% and 12.5% respectively [1] - Year-to-date, the fund is up 4.9%, while the Russell 2000 Index ETF and the Russell 2000 Value Index ETF are up 10.3% and 8.9% respectively [1] Group 2: Journey Medical Corporation Overview - Journey Medical Corporation (NASDAQ:DERM) focuses on developing and commercializing pharmaceutical products for dermatological conditions [2] - The stock of Journey Medical Corporation has seen a one-month return of 8.46% and a 52-week gain of 52.01%, closing at $7.95 per share with a market capitalization of $215.73 million on November 18, 2025 [2] Group 3: Product Launch and Financial Outlook - Journey Medical recently launched Emrosi for treating rosacea, with annualized sales nearing $30 million in the first six months post-launch, and potential peak sales exceeding $100 million based on positive feedback [3] - The company is expected to achieve profitability in 2026, supported by a scalable business model, and may be an attractive acquisition target due to ongoing consolidation in the dermatology industry [3] Group 4: Revenue and Hedge Fund Interest - Journey Medical Corporation reported revenue of $17.6 million in Q3 2025, an increase from $14.9 million in Q3 2024 [4] - The company is not among the 30 most popular stocks among hedge funds, with only 4 hedge fund portfolios holding its stock at the end of Q2 2025, down from 6 in the previous quarter [4]

Core Insights - Fortress Biotech reported a 20.5% increase in total net revenue, reaching $17.6 million for Q3 2025 compared to Q3 2024 [1] - The acquisition of Checkpoint Therapeutics by Sun Pharma resulted in Fortress receiving approximately $28 million at closing, with potential additional payments and royalties [1][2] - Dotinurad, a next-generation URAT1 inhibitor, is progressing in two Phase 3 clinical trials, supported by a $205 million Series A financing from Crystalys Therapeutics [1][2] Financial Performance - Fortress' consolidated net revenue for Q3 2025 was $17.6 million, up from $14.6 million in Q3 2024, with $17.0 million generated from dermatology products [11][19] - Consolidated net income attributable to common stockholders was $3.7 million, or $0.13 per share basic, compared to a net loss of $(15.0) million, or $(0.76) per share basic, in Q3 2024 [11][19] - Consolidated cash and cash equivalents increased to $86.2 million as of September 30, 2025, from $57.3 million at the end of 2024 [11] Corporate Developments - Fortress' Chairman highlighted strategic milestones, including the acquisition of Checkpoint and Baergic, reinforcing the company's diversified business model [2] - Journey Medical Corporation launched Emrosi™, achieving strong operational performance and expanded payer coverage, with net product revenues of $17.0 million in Q3 2025 [2][6] - The FDA issued a Complete Response Letter for CUTX-101, but the company plans to resubmit the NDA shortly [7] Clinical and Regulatory Updates - Dotinurad is advancing in two Phase 3 trials for gout treatment, with potential for best-in-class safety and efficacy [2][7] - Emrosi™ demonstrated statistical and clinical superiority over Oracea® and placebo for treating rosacea, as presented at the Fall Clinical Dermatology Conference [7] - The acquisition of Baergic by Axsome includes potential milestone payments and royalties, with Avenue Therapeutics eligible to receive approximately 74% of future payments [3]

Core Insights - Guardian Pharmacy Services (GRDN) reported quarterly earnings of $0.25 per share, exceeding the Zacks Consensus Estimate of $0.24 per share, and a significant improvement from a loss of $2 per share a year ago [1] - The company achieved revenues of $377.43 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 6.63% and showing growth from $314.39 million in the same quarter last year [3] - Guardian Pharmacy's stock has increased by approximately 42.2% since the beginning of the year, outperforming the S&P 500's gain of 14.4% [4] Earnings Performance - The earnings surprise for the recent quarter was +4.17%, following a previous surprise of +4.55% when earnings were $0.23 per share against an expectation of $0.22 [2] - Over the last four quarters, Guardian Pharmacy has exceeded consensus EPS estimates three times [2] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.25, with expected revenues of $372.06 million, and for the current fiscal year, the estimate is $0.95 on $1.4 billion in revenues [8] - The estimate revisions trend for Guardian Pharmacy was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [7] Industry Context - Guardian Pharmacy operates within the Zacks Medical - Drugs industry, which is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable industry outlook [9] - The performance of Guardian Pharmacy's stock may be influenced by the overall industry outlook and trends in earnings estimate revisions [6][9]

分组1 - electroCore, Inc. reported a quarterly loss of $0.4 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.36, and compared to a loss of $0.31 per share a year ago, indicating an earnings surprise of -11.11% [1] - The company posted revenues of $8.69 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 10.69%, and showing an increase from $6.55 million in the same quarter last year [2] - electroCore shares have declined approximately 69.5% since the beginning of the year, contrasting with the S&P 500's gain of 15.1% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.26 on revenues of $8.89 million, and for the current fiscal year, it is -$1.59 on revenues of $30.84 million [7] - The Zacks Industry Rank for Medical - Drugs is currently in the top 40% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8]

Core Insights - OmniAb, Inc. reported a quarterly loss of $0.14 per share, which aligns with the Zacks Consensus Estimate, showing an improvement from a loss of $0.16 per share a year ago [1] - The company's revenues for the quarter ended September 2025 were $2.24 million, missing the Zacks Consensus Estimate by 62.97% and down from $4.17 million year-over-year [2] - OmniAb's shares have declined approximately 58.2% year-to-date, contrasting with the S&P 500's gain of 16.5% [3] Financial Performance - The company has surpassed consensus EPS estimates only once in the last four quarters [1] - The current consensus EPS estimate for the upcoming quarter is -$0.15 on revenues of $7.15 million, and for the current fiscal year, it is -$0.59 on revenues of $21.52 million [7] Market Outlook - The earnings outlook and management's commentary during the earnings call will be crucial for assessing the stock's immediate price movement [3][4] - The Zacks Rank for OmniAb is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Industry Context - The Medical - Drugs industry, to which OmniAb belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting a favorable environment for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Group 1: Fund Performance - Summers Value Fund LP reported a net return of -1.8% in Q2 2025, underperforming the Russell 2000 Index ETF (IWM) which returned 8.5% and the Russell 2000 Value Index ETF (IWN) which returned 4.9% [1] - Year-to-date, the fund is down 12.8% net, compared to -1.8% and -3.2% returns for the respective indexes [1] Group 2: Journey Medical Corporation Overview - Journey Medical Corporation (NASDAQ:DERM) focuses on developing and commercializing pharmaceutical products for dermatological conditions [2] - The stock of Journey Medical Corporation had a one-month return of -1.35% but gained 41.47% over the last 52 weeks, closing at $7.30 per share with a market capitalization of $192.062 million on September 19, 2025 [2] Group 3: Investment Insights on Journey Medical Corporation - The fund began building a position in Journey Medical Corporation in February, highlighting its products such as Accutane for acne treatment and Qbrexza for hyperhidrosis [3] - Journey Medical Corporation generated $55 million in revenue in 2024, with a modest operating loss [3] - The company is led by CEO Claude Marauoi and a team with significant experience from Medicis, a dermatology company previously acquired for $2.6 billion [3]